SAN DIEGO, Feb. 25, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today
that senior management will provide a corporate overview at the upcoming SVB/Leerink Global Healthcare Conference, and
the Oppenheimer & Co. 29th Annual Healthcare Conference, both taking place in New York City.
A copy of the presentation materials will be made available on the company website (www.sorrentotherapeutics.com).
SVB/LEERINK Global Healthcare Conference
| Date: |
|
Thursday, February 28 |
| Time: |
|
3:30pm Eastern Time |
| Location: |
|
Lotte New York Palace Hotel |
| Webcast: |
|
http://investors.sorrentotherapeutics.com/events-and-presentations/events |
Oppenheimer & Co. 29th Annual Healthcare
Conference
| Date: |
|
Wednesday, March 20 |
| Time: |
|
2:45pm Eastern Time |
| Location: |
|
Westin Grand Central Hotel, Ambassador Room |
| Webcast: |
|
http://investors.sorrentotherapeutics.com/events-and-presentations/events |
About Sorrento Therapeutics, Inc.
Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to turn malignant
cancers into manageable and possibly curable diseases. Sorrento's multimodal multipronged approach to fighting cancer is made
possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”),
clinical stage immuno-cellular therapies (“CAR-T”), intracellular targeting antibodies (“iTAbs”), antibody-drug conjugates (“ADC”),
and clinical stage oncolytic virus (“Seprehvir®”).
Sorrento's commitment to life-enhancing therapies for patients is also demonstrated by its effort to advance a first-in-class
(TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (“RTX”), and ZTlido® (lidocaine topical system) 1.8% for
the treatment of post-herpetic neuralgia. Resiniferatoxin is completing a phase IB trial in terminal cancer patients and a phase 1B
trial in osteoarthritis patients. ZTlido® was approved by the FDA on February 28, 2018.
For more information visit www.sorrentotherapeutics.com.
Contact:
Alexis Nahama, SVP Corporate Development
Telephone: 858-203-4120
MediaRelations@SorrentoTherapeutics.com
Dan Ferry
Managing Director
LifeSci Advisors, LLC
617-535-7746
Daniel@LifeSciAdvisors.com
